[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:nras-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","NRAS Gene",8,[8,16,22,28,34,40,47,53],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:16:52.995882Z","2026-05-29T15:36:40.197011Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06096974","Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.566526Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[12],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.472498Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":45,"content_modified":46},"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",[44],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.129328Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies",[44],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.640479Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z"]